Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Johnson, D. R.
Right arrow Articles by Klaassen, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, D. R.
Right arrow Articles by Klaassen, C. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Toxicological Sciences 66, 16-26 (2002)
Copyright © 2002 by the Society of Toxicology


BIOTRANSFORMATION AND TOXICOKINETICS

Increase in Bile Flow and Biliary Excretion of Glutathione-Derived Sulfhydryls in Rats by Drug-Metabolizing Enzyme Inducers Is Mediated by Multidrug Resistance Protein 2

David R. Johnson,1, Sultan S. M. Habeebu and Curtis D. Klaassen,2

Environmental Health and Occupational Medicine Center, Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, Kansas 66160-7417

Glutathione (GSH) is an important cellular constituent for normal liver homeostasis. Certain drug-metabolizing enzyme inducers (i.e., phenobarbital [PB] and pregnenolone-16{alpha}-carbonitrile [PCN]) increase biliary excretion of GSH-derived sulfhydryls (SH) as well as bile flow, whereas other drug-metabolizing enzyme inducers (i.e., 3-methylcholanthrene [3MC] and benzo(a)pyrene [BaP]), do not. The purpose of the study was to determine whether rat multidrug resistance protein 2 (Mrp2) is the inducible transporter responsible for increasing biliary SH excretion and bile flow. Sprague-Dawley (SD) rats were injected ip daily for 4 days with PB, PCN, 3MC, BaP, or vehicle; Mrp2-null Eisai hyperbilirubinemic (EHBR) rats were injected ip daily for 4 days with PCN or vehicle. Although no drug-metabolizing enzyme inducer altered hepatic GSH in SD rats, PB and PCN significantly increased the rate of biliary SH excretion and bile flow. Neither 3MC nor BaP affected the biliary SH excretion rate or bile flow. In control EHBR rats, despite elevated hepatic GSH, the rate of biliary SH excretion was almost completely eliminated and bile flow was dramatically reduced compared with SD rats. Furthermore, PCN treatment did not affect bile flow or the biliary SH excretion rate in EHBR rats. PB and PCN also increased Mrp2 protein levels, but 3MC and BaP did not. None of the drug-metabolizing enzyme inducers tested significantly increased Mrp2 mRNA levels. PCN increased Mrp2 protein, but not Mrp2 mRNA, in a time-dependent manner. In conclusion, Mrp2 is the inducible efflux transporter responsible for increased biliary SH excretion and bile flow after administration of some drug-metabolizing enzyme inducers.

Key Words: drug-metabolizing enzyme inducers; Mrp2; glutathione; organic anion transport; EHBR.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
K.-i. Nezasa, X. Tian, M. J. Zamek-Gliszczynski, N. J. Patel, T. J. Raub, and K. L. R. Brouwer
ALTERED HEPATOBILIARY DISPOSITION OF 5 (AND 6)-CARBOXY-2',7'-DICHLOROFLUORESCEIN IN Abcg2 (Bcrp1) AND Abcc2 (Mrp2) KNOCKOUT MICE
Drug Metab. Dispos., April 1, 2006; 34(4): 718 - 723.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
N. Li, S. Choudhuri, N. J. Cherrington, and C. D. Klaassen
DOWN-REGULATION OF MOUSE ORGANIC ANION-TRANSPORTING POLYPEPTIDE 4 (Oatp4; Oatp1b2; Slc21a10) mRNA BY LIPOPOLYSACCHARIDE THROUGH THE TOLL-LIKE RECEPTOR 4 (TLR4)
Drug Metab. Dispos., November 1, 2004; 32(11): 1265 - 1271.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. L. Slitt, N. J. Cherrington, J. M. Maher, and C. D. Klaassen
INDUCTION OF MULTIDRUG RESISTANCE PROTEIN 3 IN RAT LIVER IS ASSOCIATED WITH ALTERED VECTORIAL EXCRETION OF ACETAMINOPHEN METABOLITES
Drug Metab. Dispos., September 1, 2003; 31(9): 1176 - 1186.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
N. J. Patel, M. J. Zamek-Gliszczynski, P. Zhang, Y.-H. Han, P. L. M. Jansen, P. J. Meier, B. Stieger, and K. L. R. Brouwer
Phenobarbital Alters Hepatic Mrp2 Function by Direct and Indirect Interactions
Mol. Pharmacol., July 1, 2003; 64(1): 154 - 159.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. M. Gerk and M. Vore
Regulation of Expression of the Multidrug Resistance-Associated Protein 2 (MRP2) and Its Role in Drug Disposition
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 407 - 415.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.